Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $33.00.

Several equities research analysts recently commented on URGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research note on Monday, October 27th. D. Boral Capital reiterated a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Monday, January 5th. Finally, Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Urogen Pharma Stock Down 9.5%

NASDAQ:URGN opened at $21.25 on Friday. The company’s 50 day moving average price is $23.74 and its 200-day moving average price is $19.79. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The stock has a market cap of $994.71 million, a price-to-earnings ratio of -6.14 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to the consensus estimate of $34.09 million. As a group, sell-side analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the insider directly owned 139,025 shares of the company’s stock, valued at $3,475,625. This represents a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP purchased a new position in Urogen Pharma in the third quarter worth about $84,111,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the period. Soleus Capital Management L.P. purchased a new position in shares of Urogen Pharma in the second quarter worth approximately $29,934,000. SG Americas Securities LLC boosted its holdings in shares of Urogen Pharma by 607.1% in the second quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after buying an additional 986,567 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new stake in Urogen Pharma during the third quarter valued at approximately $14,311,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.